PROCAPS GROUP S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.71 USD | +0.37% |
|
+0.74% | -33.42% |
Financials (USD)
| Sales 2023 * | 424M | Sales 2024 * | 460M | Capitalization | 306M |
|---|---|---|---|---|---|
| Net income 2023 * | 54M | Net income 2024 * | 43M | EV / Sales 2023 * | 0.72 x |
| Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 0.66 x |
| P/E ratio 2023 * |
5.65
x | P/E ratio 2024 * |
7.13
x | Employees | 5,500 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 16.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Procaps Group S.A.
More press releases
More news
| 1 day | +0.37% | ||
| 1 week | +0.74% | ||
| Current month | -6.56% | ||
| 1 month | -15.05% | ||
| 3 months | -37.56% | ||
| 6 months | +13.39% | ||
| Current year | -33.42% |
1 week
2.55
3.05
1 month
2.533.09
Current year
2.534.95
1 year
1.955.00
3 years
1.9511.98
5 years
0.0011.98
10 years
0.0011.98
| Managers | Title | Age | Since |
|---|---|---|---|
Jose Vieira
CEO | Chief Executive Officer | - | Dec. 31 |
Ruben Minski
FOU | Founder | 72 | 75-12-31 |
| Director of Finance/CFO | 51 | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| 43 | - | ||
| Director/Board Member | 64 | - | |
Kyle Bransfield
BRD | Director/Board Member | 40 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | -1.55% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 2.71 | +0.37% | 759 |
| 24-04-18 | 2.7 | +0.75% | 9,167 |
| 24-04-17 | 2.68 | +4.69% | 2,692 |
| 24-04-16 | 2.56 | -1.54% | 7,615 |
| 24-04-15 | 2.6 | -3.35% | 8,388 |
Delayed Quote Nasdaq, April 19, 2024 at 04:30 pm EDT
More quotes
Procaps Group SA is a Luxembourg-based healthcare and pharmaceutical company. The Company develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. It operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.71
USD
Average target price
4.75
USD
Spread / Average Target
+75.28%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.42% | 306M | |
| +24.60% | 654B | |
| +24.08% | 552B | |
| -5.63% | 356B | |
| +15.37% | 319B | |
| +7.38% | 295B | |
| +3.26% | 211B | |
| +0.78% | 206B | |
| -9.69% | 147B | |
| -6.63% | 144B |
- Stock Market
- Equities
- PROC Stock
